Uncategorized
Ivantis raises $27 million in financing to fund trials on microstent
Ivantis raised $27 million in a Series B round of financing for additional trials of its Hydrus microstent, according to a company news release.The device, which is about the size of an eyelash, according to the release, is designed to help re-establish the natural outflow pathway in the eyes of glaucoma patients.